Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | IDH1 R132L |
| Therapy | Vorasidenib |
| Indication/Tumor Type | astrocytoma, IDH-mutant, grade 2 |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH1 R132L | astrocytoma, IDH-mutant, grade 2 | sensitive | Vorasidenib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial l (INDIGO) that supported FDA approval, Voranigo (vorasidenib) treatment significantly improved progression-free survival (27.7 vs 11.1 months, HR 0.39, p<0.001) and time to next intervention (HR 0.26, p<0.001) compared to placebo in adult and pediatric patients 12 years and older with WHO grade 2 astrocytoma or oligodendroglioma harboring susceptible IDH1 or IDH2 mutations, including IDH1 R132H/C/G/L/S (PMID: 37272516; NCT04164901). | detail... detail... 37272516 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Full reference... | ||
| (37272516) | Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. | Full reference... |
| Voranigo (vorasidenib) FDA Drug Label | Full reference... |